Goofice (elobixibat) / Ferring, Eisai, Mochida, Ipsen - LARVOL DELTA

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL (UEGW 2026) - "Elobixibat treatment showed a promising short-term effect on liver stiffness improvement, with statistically significant LSM at the 15 mg dose and favourable fibrosis-stage shift across treatment arms. CAP reduction appeared greatest with the 10 mg dose. Treatment was generally well tolerated, although gastrointestinal adverse events were more common in the elobixibat groups."

Clinical • Fibrosis • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatotic Liver Disease

Efficacy and Safety of Elobixibat for Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis (ACG 2026) - "The nausea rate of 0.2% is substantially lower than the 15-32% reported with lubiprostone. Twenty-three studies (N >9,000) were included. Elobixibat significantly increased weekly SBM by 3.04/week (95% CI 2.34-3.73; k=14; I 2 =97.7%) and improved BSFS by 1.33 points (95% CI 1.03-1.63; k=13; I 2 =95.5%). Nearly 80% (95% CI 68.1-89.5; k=6) of patients achieved SBM within 24 hours of first dose."

Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

Repurposing Elobixibat for Genetic Cholestasis. (PubMed, J Clin Exp Hepatol) - No abstract available

Journal • Cholestasis • Hepatology

Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report. (PubMed, Case Rep Gastroenterol) - "Constipation is a common, dose-dependent adverse effect of incretin-based anti-obesity therapies that affects patient adherence and may necessitate discontinuation, resulting in loss of metabolic benefits and weight regain. Elobixibat, an ileal bile acid transporter (IBAT) inhibitor, may offer a targeted alternative when conventional laxatives fail...Lactulose, psyllium, stimulant laxatives, and polyethylene glycol were ineffective or poorly tolerated, leading to painful perianal fissures...Therefore, a prospective evaluation is recommended. IBAT inhibition may represent a mechanism-based strategy to overcome the specific motility deficits induced by incretin therapy."

Journal • Constipation • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypertriglyceridemia • Obesity • Pain

Editorial: Comparative Effectiveness in Chronic Constipation-Interpreting Real-World Evidence. (PubMed, Aliment Pharmacol Ther) - No abstract available

HEOR • Journal • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder

Exploring the Treatment Outcomes and Safety of Elobixibat for Chronic Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Acta Med Indones) - "Elobixibat shows promising therapeutic efficacy in the treatment of functional chronic constipation. Elobixibat is safe and well-tolerated with minimal adverse events."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder

Feasibility and tolerability of reduced-volume oral sulfate solution combined with elobixibat for bowel preparation before colonoscopy: a single-center pilot study. (PubMed, Gastroenterol Rep (Oxf)) - "Reduced OSS volume may be achievable in selected patients. However, these findings are limited to a relatively low-risk, non-elderly population and should be confirmed in larger comparative studies."

Journal

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study. (PubMed, Aliment Pharmacol Ther) - "This head-to-head comparative study demonstrates that elobixibat provides superior overall symptomatic relief and quality-of-life improvement compared with prucalopride, potentially due to its dual mechanism of action. These findings support the consideration of IBAT inhibition as a second-line treatment option in patients with FC."

HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

A prospective, randomized, single-center trial: elobixibat/PEG vs. bisacodyl/PEG for bowel preparation (IDDF 2026) - "Crucially, Elobixibat, as an adjunct to PEG, is a viable alternative to the current standard of care (Bisacodyl/PEG), offering similar efficacy with better tolerability. These findings support the use of Elobixibat to optimize bowel preparation strategies, ultimately improving patient experience and comfort without compromising colonoscopy quality."

Clinical • CNS Disorders • Colorectal Cancer • Sleep Disorder • Solid Tumor

Renal apical sodium-dependent bile acid transporter (ASBT) inhibition increases whole-body bile acid clearance in healthy pigs by enabling renal elimination as quantified by 11C-CSar PET/CT (EASL 2026) - "Intravenous administration of elobixibat increased whole-body clearance of BA in healthy pigs by enabling renal elimination. These findings provide a translational rationale for systemic ASBT inhibition as a strategy to reduce systemic bile acid exposure in patients with severe cholestasis, including patients at risk of cholaemic nephropathy."

Clinical • Cholestasis • Hepatology • Renal Disease

Apical sodium-dependent bile acid transporter (ASBT) inhibition improves hepatic and extrahepatic manifestations in a mouse model of cirrhosis (EASL 2026) - "Here, we evaluated the role of the sodium-dependent bile acid transporter (ASBT) in a mouse model of cirrhosis, using either a gut-restricted ASBT inhibitor (elobixibat) or a systemic ASBT inhibitor (ritivixibat)... ASBT inhibition restores bile acid homeostasis and significantly improves hepatic and extrahepatic features of advanced fibrosis, supporting its potential as a therapeutic strategy for advanced liver disease."

Preclinical • Cardiovascular • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Portal Hypertension

Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan. (PubMed, Front Psychiatry) - "Elobixibat improved chronic constipation with no new safety signal identified in patients with schizophrenia or depression and with available follow-up in real-world settings. https://jrct.mhlw.go.jp/latest-detail/jRCT1080223950, identifier jRCT1080223950."

Journal • P4 data • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Impact of Chronic Constipation and Subtypes on Serum Trimethylamine-N-oxide Levels and Their Reduction with Treatment: Multicenter Observational Study. (PubMed, Clin Transl Gastroenterol) - "Constipation status, particularly STC, is associated with elevated serum TMAO levels. MgO or elobixibat significantly reduced serum TMAO, with a greater reduction observed with elobixibat."

Journal • Observational data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder

Efficacy and Safety of Elobixibat in Patients with Chronic Constipation: A Meta-Analysis of Randomized Controlled Trials (APASL 2026) - No abstract available

Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder

Ileal bile acid transporter inhibitors for chronic constipation in the elderly. (PubMed, World J Gastrointest Pharmacol Ther) - "The authors have not commented on the exclusion of possible drug-related constipation, as most of their elderly patients have comorbid illness, structural causes of constipation, evaluation of gastrointestinal motility, and advocating for a more comprehensive workup for CC in the elderly. This article also provides a comprehensive review of the workup of CC in the elderly, as well as a review of the available evidence on ileal bile acid transporter inhibitor - elobixibat in CC."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Short-Term Efficacy and Safety of Elobixibat for Chronic Constipation Assessed by Rectal Ultrasonography: A Retrospective Observational Study. (PubMed, Diagnostics (Basel)) - "Adverse events included abdominal distension and abdominal pain, each observed in one patient (3.1%). Elobixibat was effective and well tolerated in patients with chronic constipation classified by rectal US findings."

Journal • Observational data • Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia. (PubMed, J Neurogastroenterol Motil) - "First line therapies such as dietary-fiber optimization and osmotic laxatives are widely available, but newer pharmacotherapies (prucalopride, linaclotide, lubiprostone, and elobixibat) remain costly and unevenly accessible. The Bali Chronic Constipation Roundtable highlighted Asia's need for region specific diagnostics and management. Addressing diagnostic and treatment gaps will improve outcomes, while ongoing researcher clinician policy collaboration must standardize guidelines, advance research, and ensure equitable care across Asia."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Cost-utility analysis of treatment strategies for chronic constipation in Japan. (PubMed, J Gastroenterol) - "The lubiprostone-elobixibat-PEG formulation strategy showed the most favorable cost-effectiveness profile. In addition, novel treatment options, including lubiprostone, linaclotide, elobixibat, and PEG formulation, were found to be cost-effective compared to MgO. Further research is warranted to confirm these findings and support their application in clinical practice."

HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Socioeconomic value of treatments for chronic idiopathic constipation in Japan. (PubMed, BMC Gastroenterol) - "Considering CIC-related medical costs, QoL, productivity loss, and caregiver burden, elobixibat 10 mg is associated with better QoL and lower costs than linaclotide 0.5 mg and lubiprostone 48 μg."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Laxative logic: when lifestyle is not enough. (PubMed, Curr Opin Gastroenterol) - "Patients with constipation now have access to a wide range of medications, from over-the-counter osmotic and stimulant agents to prescription laxative combination strategies. This breadth allows clinicians to tailor therapy to diverse pathophysiology and symptom profiles. Yet despite this choice, real-world adherence remains poor and many patients are dissatisfied, reflecting the complexity of treating constipation and frequent mismatches between therapy and patients' most bothersome symptoms. Management should emphasize careful symptom assessment, shared decision-making, and clear expectation setting, while leveraging the available armamentarium."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Carrier cross-reactivities of the bile acid reabsorption inhibitors elobixibat, linerixibat, maralixibat, and odevixibat. (PubMed, J Lipid Res) - "In contrast, this mutation had no significant effect on the ASBT inhibition by elobixibat, maralixibat, and odevixibat, indicating distinct binding sites. In conclusion, the analyzed BARIs revealed carrier cross-reactivities with NTCP, SOAT, and members of the OATP family, but behaved differently regarding their time-dependent inhibition and potential inhibitor binding sites."

Journal • Hepatitis B • Infectious Disease • Inflammation • SLCO2B1

Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation. (PubMed, JGH Open) - "Elobixibat increases the total fecal bile acid concentration of CC patients, which results in shortened colonic transit time. Trial Registration: JRCT ID: jRCTs061200030; https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs061200030."

Clinical • Journal • Colorectal Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder

Efficacy of elobixibat for elderly patients with chronic constipation in a clinic. (PubMed, World J Gastrointest Pharmacol Ther) - "Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison of the Effectiveness of Magnesium Oxide and Elobixibat on Improving Rectal Sensitivity and Colonic Transit Time in Patients With Chronic Constipation: An Observational Study. (PubMed, Neurogastroenterol Motil) - "EXB demonstrated significantly greater improvements of LODD, rectal sensation, and CTT compared to MgO."

Journal • Observational data • Constipation • Gastroenterology • Gastrointestinal Disorder

ANALYSES OF THE SOCIOECONOMIC VALUES OF TREATMENTS FOR CHRONIC CONSTIPATION IN JAPAN (DDW 2025) - "Methods Using data from clinical trials of Lubiprostone, Linaclotide, and Elobixibat conducted in Japan, changes in the number of spontaneous bowel movements (SBM) were synthesized using network meta-analysis (NMA), with placebo results set at zero for comparison. Sensitivity Analysis: The results were sensitive to the effectiveness of Elobixibat, but the trend remained consistent with the base case analysis for the other costs. Conclusions When selecting constipation treatment drugs, it is essential to consider not only their efficacy and cost but also their potential to reduce the socioeconomic burden associated with chronic constipation."

Constipation • Gastroenterology • Gastrointestinal Disorder